We recently presented on a hot-button topic in the world of drug pricing, "Prescription Drug Affordability Boards (PDABs): Overview, Challenges, and Recommend Strategies."  This presentation provides an informative overview for pharmaceutical manufacturers by covering the following aspects:

• The reasons why there so many PDABs being established
• The current PDAB landscape in the US
• PDAB authority & tools
• Pharmaceutical Manufacturer burdens
• Legal Challenges
• Example of affordability reviews and consequences
• Interactions of Federal and State Controls
• Next steps: What manufacturers need to think about

If you are interested in receiving a copy of the presentation, please enter your information in the contact form below and we will automatically provide you with a copy.

On Tuesday, January 21, 2025, the Garden State officially opened the registration process for its State Price Transparency Reporting (SPTR) program.  This means that drug manufacturers who meet the reporting criteria must now register with the Drug Affordability Unity at the NJ Division of Consumer Affairs and prepare to comply with the state's drug price transparency requirements.

All reporting entities - including drug manufacturers - have a short window to register; registration is required by January 31, 2025.

To register, manufacturers must use the Excel spreadsheet template provided.  For additional guidance, you may refer to the Data Collection Manual.  While not explicitly stated in the Manual, it appears that the "entity type" for drug manufacturers should be: "Manufacturer."  Moreover, it appears that completed registration forms should be emailed to: [email protected].

As a reminder, in NJ, reporting of applicable price increases and new drugs already went into effect on August 1, 2024.

To visit the NJ registration page for more info, please see here.

2024 was a record-setting year for new State Drug Price Transparency Reporting (SPTR) requirements.  From California to New Jersey, North Dakota to Texas, Maine to New Mexico, Washington to Florida, we've seen new SPTR laws enacted in every area of the country and across the political spectrum.

But brace yourselves because 2025 is picking up right where we left off.  In fact, while we are just a few days into the new year, we already have one of our first bills in New York that is proposing new SPTR requirements (in addition to the NY law that was already enacted last year)!

Already managing perpetual SPTR requirements in 15+ states with 30+ price increase calculations (not to mention new drug notifications and similar reporting ) is enough to make your head spin.  To alleviate this burden and help avoid potential regulatory scrutiny by exceeding price increase thresholds (not to mention severe enforcement penalties which have already been levied against the industry), our clients have trusted our cost-effective reporting services and first-of-its-kind software platform, Rx Price Transparency Tracker, which provides instant analysis on drug pricing considerations and their regulatory impact.

We've started this blog to help keep the industry informed of SPTR (and Spend Transparency) reporting requirements.

Keep checking back for more updates.  In the meantime, we hope you had no issues submitting the Louisiana SPTR report and have submitted or are about to submit the other January SPTR reports, such as North Dakota, Texas, West Virginia, Maine, Pennsylvania, and California.  Good luck!